# DoD Neurofibromatosis Clinical Trial Award

Source: https://welltoldgrants.com/grants/ht9425-23-nfrp-cta-dod-neurofibromatosis-clinical-trial-award/  
Official notice: https://www.grants.gov/search-results-detail/348282

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $1.6 million in total. Applications closed on October 5, 2023.

| Field | Value |
|---|---|
| Opportunity number | HT9425-23-NFRP-CTA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | October 5, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $1.6 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. The vision of the FY23 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and Schwannomatosis. Areas of Emphasis: The FY23 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the Areas of Emphasis listed below. All applications are also encouraged to include materials and data from diverse populations in their research. • NF2 and Schwannomatosis-related areas (e.g., hearing, balance, schwannoma, ependymoma, meningioma, LZTR1, SMARCB1) • Endpoint validation, biomarker discovery, and technological innovation for assessments • Application of data science • Non-tumor manifestations not limited to: o Pain o Cognitive manifestations o Sleep

## Questions people ask

### Is HT9425-23-NFRP-CTA still open?

No. It closed on October 5, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Neurofibromatosis Clinical Trial Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Neurofibromatosis Clinical Trial Award?

Closed October 5, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $1.6 million in total for one award.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.